Outcome prediction of oestrogen receptor‐positive breast cancer based on a panel of oestrogen receptor‐regulated genes

The response of oestrogen receptor‐positive (ER+) breast cancers (BC) to endocrine therapy (ET) is variable. ER pathway‐regulated genes have been proposed to play a role in response to ET. In this study, we investigated the prognostic and predictive impacts of the expression of key ER‐regulated genes in BC.

• Publication year

  2025

• Venue

  Histopathology

• Publication date

  2025-09-12

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/his.15557PMID 40937605PMCID 12605772
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Estrogen Receptor Signaling in Breast Cancer

  2023cited by this paper
• Clinicopathological Significance and Expression Pattern of Bcl2 in Breast Cancer: A Comprehensive in silico and in vitro Study

  2023cited by this paper
• Quantitative expression of oestrogen receptor in breast cancer: Clinical and molecular significance.

  2023cited by this paper
• The clinical value of progesterone receptor expression in luminal breast cancer: A study of a large cohort with long‐term follow‐up

  2023cited by this paper
• Estrogen receptor positive breast cancers have patient specific hormone sensitivities and rely on progesterone receptor

  2022cited by this paper
• Ki67 assessment in invasive luminal breast cancer: a comparative study between different scoring methods

  2022cited by this paper
• Novel estrogen-responsive genes (ERGs) for the evaluation of estrogenic activity

  2022cited by this paper
• Emerging role of pioneer transcription factors in targeted ERα positive breast cancer

  2021cited by this paper
• The reactome pathway knowledgebase 2022

  2021cited by this paper
• The Incidence of Breast Cancer Recurrence 10-32 Years After Primary Diagnosis

  2021cited by this paper
• Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancer

  2021cited by this paper
• Oestrogen-regulated protein SLC39A6: a biomarker of good prognosis in luminal breast cancer

  2021cited by this paper
• Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

  2021cited by this paper
• Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update.

  2020cited by this paper
• Trefoil factor 1 (TFF1) is a potential prognostic biomarker with functional significance in breast cancers.

  2020cited by this paper
• The Biological and Clinical Significance of Glutaminase in Luminal Breast Cancer

  2020cited by this paper
• Estradiol-Induced Epigenetically Mediated Mechanisms and Regulation of Gene Expression

  2020cited by this paper
• An estrogen receptor (ER)‐related signature in predicting prognosis of ER‐positive breast cancer following endocrine treatment

  2019cited by this paper
• iDEP: an integrated web application for differential expression and pathway analysis of RNA-Seq data

  2018cited by this paper
• The amino acid transporter SLC7A5 confers a poor prognosis in the highly proliferative breast cancer subtypes and is a key therapeutic target in luminal B tumours

  2018cited by this paper
• Tamoxifen Resistance in Breast Cancer Is Regulated by the EZH2-ERα-GREB1 Transcriptional Axis.

  2018cited by this paper
• Signaling pathways and steroid receptors modulating estrogen receptor α function in breast cancer

  2018cited by this paper
• Role for Growth Regulation by Estrogen in Breast Cancer 1 (GREB1) in Hormone-Dependent Cancers

  2018cited by this paper
• GREB1 is an estrogen receptor-regulated tumour promoter that is frequently expressed in ovarian cancer

  2018cited by this paper
• Androgen receptor in estrogen receptor positive breast cancer: Beyond expression.

  2017cited by this paper
• Tumor Heterogeneity in Breast Cancer

  2017cited by this paper
• Prognostic stratification of oestrogen receptor‐positive HER2‐negative lymph node‐negative class of breast cancer

  2017cited by this paper
• ER-positive breast cancer cells are poised for RET-mediated endocrine resistance

  2017cited by this paper
• 20‐Year Risks of Breast‐Cancer Recurrence after Stopping Endocrine Therapy at 5 Years

  2017cited by this paper
• Revisiting the IGF-1R as a breast cancer target

  2017cited by this paper
• Impact of intratumoural heterogeneity on the assessment of Ki67 expression in breast cancer

  2016cited by this paper
• Bimodality of intratumor Ki67 expression is an independent prognostic factor of overall survival in patients with invasive breast carcinoma

  2016cited by this paper
• Prognostic significance of androgen receptor expression in invasive breast cancer: transcriptomic and protein expression analysis

  2016cited by this paper
• TFF3 is a valuable predictive biomarker of endocrine response in metastatic breast cancer

  2015cited by this paper
• Progesterone receptor modulates estrogen receptor-α action in breast cancer

  2015cited by this paper
• Endocrine resistance in breast cancer--An overview and update.

  2015cited by this paper
• Expression of androgen receptor splice variants in clinical breast cancers

  2015cited by this paper
• The pioneer factor PBX1 is a novel driver of metastatic progression in ERα-positive breast cancer

  2015cited by this paper
• Brain-Expressed X-linked (BEX) proteins in human cancers.

  2015cited by this paper
• Revising the role of the androgen receptor in breast cancer.

  2014cited by this paper
• Identification of estrogen-responsive genes based on the DNA binding properties of estrogen receptors using high-throughput sequencing technology

  2014cited by this paper
• Updated UK Recommendations for HER2 assessment in breast cancer

  2014cited by this paper
• Endocrine resistance in breast cancer

  2014cited by this paper
• BEX1 Promotes Imatinib-Induced Apoptosis by Binding to and Antagonizing BCL-2

  2014cited by this paper
• RNA Sequencing of MCF-7 Breast Cancer Cells Identifies Novel Estrogen-Responsive Genes with Functional Estrogen Receptor-Binding Sites in the Vicinity of Their Transcription Start Sites

  2013cited by this paper
• Endogenous purification reveals GREB1 as a key estrogen receptor regulatory factor.

  2013cited by this paper
• bc-GenExMiner 3.0: new mining module computes breast cancer gene expression correlation analyses

  2013cited by this paper
• The trefoil factor 1 (TFF1) protein involved in doxorubicin‑induced apoptosis resistance is upregulated by estrogen in breast cancer cells.

  2013cited by this paper
• Tamoxifen Resistance in Breast Cancer

  2012cited by this paper
• Life stage differences in mammary gland gene expression profile in non-human primates

  2012cited by this paper
• bc-GenExMiner: an easy-to-use online platform for gene prognostic analyses in breast cancer

  2012cited by this paper
• PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2

  2012cited by this paper
• FOXA1 is an independent prognostic marker for ER-positive breast cancer

  2012cited by this paper
• The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups

  2012cited by this paper
• Progesterone receptor action: defining a role in breast cancer

  2011cited by this paper
• Serum estradiol levels associated with specific gene expression patterns in normal breast tissue and in breast carcinomas

  2011cited by this paper
• Identification of Gene Expression Signature in Estrogen Receptor Positive Breast Carcinoma

  2010cited by this paper
• Correlation of GREB1 mRNA with protein expression in breast cancer: validation of a novel GREB1 monoclonal antibody

  2010cited by this paper
• Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies

  2010cited by this paper
• Predicting endocrine therapy responsiveness in breast cancer.

  2009cited by this paper
• AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist

  2009cited by this paper
• Role of ErbB4 in Breast Cancer

  2008cited by this paper
• Forkhead-box A1 (FOXA1) expression in breast cancer and its prognostic significance.

  2008cited by this paper
• Novel estrogen receptor-alpha binding sites and estradiol target genes identified by chromatin immunoprecipitation cloning in breast cancer.

  2007cited by this paper
• Long-range activation of GREB1 by estrogen receptor via three distal consensus estrogen-responsive elements in breast cancer cells.

  2007cited by this paper
• The p53 positive Bcl‐2 negative phenotype is an independent marker of prognosis in breast cancer

  2007cited by this paper
• BEX2 is overexpressed in a subset of primary breast cancers and mediates nerve growth factor/nuclear factor-kappaB inhibition of apoptosis in breast cancer cell lines.

  2007cited by this paper
• Identifying estrogen receptor target genes

  2007cited by this paper
• FOXA1 Expression in Breast Cancer—Correlation with Luminal Subtype A and Survival

  2007cited by this paper
• Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers.

  2006cited by this paper
• Prognostic Relevance of AGR2 Expression in Breast Cancer

  2006cited by this paper
• Estrogen receptor target gene: an evolving concept.

  2006cited by this paper
• Gene expression signature of estrogen receptor α status in breast cancer

  2005cited by this paper
• Immunohistochemical study of androgen receptors in breast carcinoma. Evidence of their frequent expression in lobular carcinoma

  2005cited by this paper
• Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy.

  2005cited by this paper
• High‐throughput protein expression analysis using tissue microarray technology of a large well‐characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses

  2005cited by this paper
• Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis.

  2005cited by this paper
• GREB1 is a critical regulator of hormone dependent breast cancer growth

  2005cited by this paper
• X-Tile

  2004cited by this paper
• Transcriptional profiling of estrogen-regulated gene expression via estrogen receptor (ER) alpha or ERbeta in human osteosarcoma cells: distinct and common target genes for these receptors.

  2004cited by this paper
• Prediction of prognosis of estrogen receptor‐positive breast cancer with combination of selected estrogen‐regulated genes

  2004cited by this paper
• Discovery of estrogen receptor α target genes and response elements in breast tumor cells

  2004cited by this paper
• Predicting the clinical status of human breast cancer by using gene expression profiles

  2001cited by this paper
• Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns.

  2001cited by this paper
• Expression of somatostatin type 2A receptor correlates with estrogen receptor in human breast carcinoma

  2000cited by this paper
• PDZK1 and GREB1 are estrogen-regulated genes expressed in hormone-responsive breast cancer.

  2000cited by this paper
• Immunohistochemical analysis of apocrine breast lesions. Consistent over-expression of androgen receptor accompanied by the loss of estrogen and progesterone receptors in apocrine metaplasia and apocrine carcinoma in situ.

  1997cited by this paper

• No citing papers are available for this paper.